Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of intensified gemcitabine + cisplatin versus MVAC in advanced urothelial cancer
ACTRN12610000845033Phase 3Completed
- Sponsor
- HeCOG
- Start
- Nov 2003
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, cisplatin, methotrexate, vinblastine and doxorubicin in transitional cell carcinoma (TCC) (2 arms), sponsored by HeCOG. Primary endpoint: Overall survival. Started Nov 2003; status: completed.
02
Drugs
gemcitabinecisplatinmethotrexatevinblastinedoxorubicin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ACTRN12610000845033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000845033.